WCMNY
CTOR

Westchester Capital Management (New York)’s Citius Oncology CTOR Stock Holding History

Westchester Capital Management (New York)’s Portfolio CTOR Stock Details CTOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-300,000
Closed -$3.4M – 210
2024
Q2 		$3.4M Hold
300,000
– – 0.13% 96
2024
Q1 		$3.32M Hold
300,000
– – 0.12% 110
2023
Q4 		$3.29M Hold
300,000
– – 0.12% 119
2023
Q3 		$3.22M Hold
300,000
– – 0.09% 148
2023
Q2 		$3.16M Hold
300,000
– – 0.1% 172
2023
Q1 		$3.12M Hold
300,000
– – 0.09% 211
2022
Q4 		$3.05M Buy
+300,000
New +$3.04M 0.08% 241

Other funds holding CTOR

YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Westchester Capital Management (New York)'s CTOR Position: Q3 2024 in Review

Westchester Capital Management (New York) sold out of Citius Oncology (CTOR) in Q3 2024, closing a stake of 300,000 shares — an estimated $3.4M sold.

Westchester Capital Management (New York) first reported a position in CTOR in Q4 2022 and held it in 7 quarters. The position peaked at $3.4M in Q2 2024. 7 funds tracked by Wall St. Rank hold CTOR as of Q3 2024.

  • Westchester Capital Management (New York) reported no remaining Citius Oncology position as of Q3 2024 after selling out during the quarter.
  • Westchester Capital Management (New York) sold 300,000 Citius Oncology shares in Q3 2024, an estimated $3.4M.
  • Westchester Capital Management (New York) first reported a position in Citius Oncology in Q4 2022 and held it in 7 quarters.
  • Westchester Capital Management (New York)'s Citius Oncology position peaked at $3.4M in Q2 2024.
  • 7 funds tracked by Wall St. Rank held Citius Oncology as of Q3 2024.

Based on Westchester Capital Management (New York)'s 13F filing for Q3 2024, filed 14 Nov 2024.